Clinical trials: FEV1
Pulmonary Disease, Chronic Obstructive
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive…
- Trial name
- ECLIPSE (NCT00292552)
- Testing
- Novel endpoint determination
- Where
- 44 sites in United States, Bulgaria and 10 more
- Volunteers
- 2,747 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00932646
- Testing
- BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Foradil
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)
This is a randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of twenty-seven day- repeat inhaled daily doses of GW870086X on forced expiratory volume in 1 second (FEV1).
- Trial name
- NCT01245426
- Testing
- GW870086 2mg, GW870086 4mg, GW870086 1mg
- Where
- 11 sites in Bulgaria, Germany and 1 more
- Volunteers
- 136 people
- Sponsor
- GlaxoSmithKline
Hyperreactive Airway Disease
Methacholine Challenge Test (MCT) in Healthy Adults
Knowledge of Methacholine Challenge Test (MCT) and impedance Oscillometry (IOS) is limited. Only three studies have included adult patients, and none of these with healthy controls.
- Trial name
- NCT06509659
- Testing
- Methacholine Challenge Test
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Allergi- og Lungeklinikken, Elsinore
COPD
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
The purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.
- Trial name
- NCT00422552
- Testing
- Indacaterol (QAB149)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease With Exacerbation
Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype
"The study is a randomized controlled trial comparing roflumilast and azithromycin as add-on therapies in 70 patients with severe chronic obstructive pulmonary disease (COPD ) and frequent exacerbations.
- Trial name
- COPD (NCT07795086)
- Testing
- Roflumilast Oral Tablet, Azithromycin 250 mg
- Volunteers
- 70 people
- Sponsor
- Sidra Aziz
Asthma
Investigation Of A New Medication (GW642444) In Asthmatic Patients
This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat inhaled doses of GW642444.
- Trial name
- NCT00354874
- Testing
- GW642444, salmeterol 50mcg
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease), COPD
Dupilumab in Type 2-Inflamed COPD Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study
This multicentre retrospective cohort study describes lung function and patient-reported outcomes in adults with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received add-on dupilumab in routine…
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD, Eosinophilia
- Trial name
- DUPICENTRO (NCT07788092)
- Testing
- Dupilumab
- Where
- 6 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera di Perugia
Healthy
Spirometry Using Electrical Impedance Tomography
The main aim of this study is to test spirometry measurements using EIT with a calibration using tidal volume obtained from the simultaneous standard spirometry measurement.
- Trial name
- EIT (NCT03746795)
- Testing
- Spirometric examinations realized using the EIT, Simultaneous measurement by spirometer and EIT
- Where
- Czechia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Czech Technical University in Prague
Asthma Childhood
This Study Aims to Compare Asthma Control in Children Monitored With FeNO Against a Historical Cohort Without FeNO. Secondary Objectives Include Evaluating Associations Between FeNO Levels, ACT/C-ACT Scores, Eosinophil Counts, FEV1%, ICS Adherence, and Exacerbation Frequency.
This study aims to evaluate whether incorporating FeNO monitoring into routine pediatric asthma care improves clinical outcomes relative to a historical cohort managed without FeNO
- Trial name
- NCT07788534
- Testing
- FENO, PFT
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 80 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Asthma
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
- Trial name
- NCT01070524
- Testing
- CHF 5188 pMDI, Budesonide extrafine pMDI, Seretide(r) Evohaler(r)
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with…
- Trial name
- NCT01808339
- Testing
- Fluticasone Furoate (FF)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Flutiform® Compared With Seretide® in the Treatment of COPD
The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02195375
- Testing
- Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID
- Where
- 5 sites in Australia, China and 3 more
- Volunteers
- 923 people
- Sponsor
- Mundipharma Research Limited
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00931385
- Testing
- BI 1744, bi1744, Foradil
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Sickle Cell Disease
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
Sickle cell anemia (SCA) is a life-threatening, monogenic disorder associated with early death when compared to individuals without SCA.
- Trial name
- NCT02960503
- Testing
- Azithromycin
- Where
- United States
- Sponsor
- Vanderbilt University
Cystic Fibrosis
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
The purpose of this study is to determine the efficacy and safety of chronic treatment with inhaled dry powder mannitol in subjects with cystic fibrosis.
- Trial name
- NCT00446680
- Testing
- Mannitol
- Where
- 29 sites in Australia, Ireland and 1 more
- Volunteers
- 340 people
- Sponsor
- Syntara
Asthma, Efficacy
A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
This study will be a randomised, double-blind, multiple dose (14 days), placebo-controlled, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild…
- Conditions
- Asthma, Efficacy, Safety
- Trial name
- NCT02479412
- Testing
- 800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily
- Where
- 10 sites in Bulgaria, Germany
- Volunteers
- 54 people
- Sponsor
- AstraZeneca